echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Cardiovasc Diabetol: Establishment and validation of a model for predicting cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus complicated with atherosclerotic cardiovascular disease

    Cardiovasc Diabetol: Establishment and validation of a model for predicting cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus complicated with atherosclerotic cardiovascular disease

    • Last Update: 2022-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Type 2 diabetes mellitus (T2DM) is common in individuals with atherosclerotic cardiovascular disease (ASCVD) and increases the risk of
    morbidity and mortality.


    Ideally, treatment decisions for these patients are determined by the potential risk of cardiovascular complications in the
    patient.


    Purpose: In this study, our aim was to develop a model that predicts the mid-term ASCVD events in trials using siagliptin (TECOS) to assess cardiovascular outcomes in individuals with both T2DM and ASCVD, and to externally validate the findings
    of ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial participants.


    Methods: Using sitagliptin (TECOS) to evaluate data from cardiovascular outcome trials, we used a Cox proportional risk model to predict MACE in patients with T2DM and ASCVD
    .


    Results: Overall, 1491 (10.


    Table 1 uses the multivariate of the extended risk score to adjust the model output parameters

    Figure 1 Prediction and 4-year incidence of major cardiovascular adverse events (MACEs) based on simplified and extended risk scores for predicted risk decimal digits
    .


    Table 2 uses the variables in the delicacy risk score to adjust the model output parameters using the variables

    Figure 2 Cumulative incidence of MACE in the quintiles of risk scores in the A Derivation (TECOS) and B Validation (ACCORD) cohorts
    .


    Conclusion: In patients with T2DM and ASCVD, this 9-factor risk model can quantify the risk of complications of future ASCVD and inform treatment and intensity decisions
    .


    Stevens SR, Segar MW, Pandey A, Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.